PMID- 28888936
OWN - NLM
STAT- MEDLINE
DCOM- 20171103
LR  - 20220408
IS  - 1090-2422 (Electronic)
IS  - 0014-4827 (Linking)
VI  - 360
IP  - 2
DP  - 2017 Nov 15
TI  - beta-arrestin-2 is involved in irisin induced glucose metabolism in type 2 diabetes 
      via p38 MAPK signaling.
PG  - 199-204
LID - S0014-4827(17)30476-7 [pii]
LID - 10.1016/j.yexcr.2017.09.006 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a common metabolic disease worldwide. It has 
      been reported that irisin play regulatory role in glucose metabolism in T2DM. 
      However, the underlying mechanism involved in that is not completely known. 
      Herein, we determined the novel role of beta-arrestin-2 in irisin-induced glucose 
      utilization in diabetes. Effects of irisin and beta-arrestin-2 on glucose 
      utilization were investigated in a rat model of diabetes and in diabetic C2C12 
      cells in vitro. Results showed that irisin had positive role in glucose 
      metabolism via regulating glucose tolerance as well as uptake in cardiac and 
      skeletal muscle tissues, as evidenced by IPGTT, 2-deoxyglucose uptake and plasma 
      membrane GLUT-4 assay. beta-arrestin-2 also improved glucose utilization in diabetes 
      by increasing the glucose uptake and insulin sensitivity, as shown in mice 
      overexpressing beta-arrestin-2. In diabetic C2C12 myocytes, irisin-induced GLUT4 and 
      glucose uptake were restrained by beta-arrestin-2 inhibition, but was enhanced by 
      beta-arrestin-2 overexpression. Additionally, irisin and beta-arrestin-2 increased the 
      activation of p38 MAPK in diabetic C2C12 cells, and the repression of p38 MAPK 
      activation decreased the glucose uptake and plasma membrane GLUT-4 was enhanced 
      by irisin and beta-arrestin-2 overexpression in diabetic C2C12 cells. In conclusion, 
      we demonstrated that beta-arrestin-2 has a crucial role in irisin induced glucose 
      metabolism in T2DM by regulating the p38 MAPK signaling. This might present a 
      novel therapeutic target of treatment for human diabetes.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Pang, Yaling
AU  - Pang Y
AD  - Department of Endocrinology, Shaanxi Provincial People's Hospital, Xi'an 710068, 
      Shaanxi, China.
FAU - Zhu, Haihui
AU  - Zhu H
AD  - Department of Endocrinology, Shaanxi Province TCM Hospital, Xi'an 710003, 
      Shaanxi, China.
FAU - Xu, Jianqin
AU  - Xu J
AD  - Department of Endocrinology, Shaanxi Province TCM Hospital, Xi'an 710003, 
      Shaanxi, China.
FAU - Yang, Lihua
AU  - Yang L
AD  - Department of Ophthalmology, Shaanxi Provincial People's Hospital, Xi'an 710068, 
      Shaanxi, China.
FAU - Liu, Lingjiao
AU  - Liu L
AD  - Department of Endocrinology, Shaanxi Provincial People's Hospital, Xi'an 710068, 
      Shaanxi, China.
FAU - Li, Jing
AU  - Li J
AD  - Department of Traditional Chinese Medicine, Shaanxi Provincial People's Hospital, 
      Xi'an 710068, Shaanxi, China. Electronic address: jinglishaan@163.com.
LA  - eng
PT  - Journal Article
DEP - 20170906
PL  - United States
TA  - Exp Cell Res
JT  - Experimental cell research
JID - 0373226
RN  - 0 (Arrb2 protein, rat)
RN  - 0 (FNDC5 protein, rat)
RN  - 0 (Fibronectins)
RN  - 0 (beta-Arrestin 2)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Carbohydrate Metabolism/genetics
MH  - Cells, Cultured
MH  - Diabetes Mellitus, Experimental/*genetics/*metabolism
MH  - Diabetes Mellitus, Type 2/*genetics/*metabolism
MH  - Fibronectins/*physiology
MH  - Glucose/*metabolism
MH  - MAP Kinase Signaling System/physiology
MH  - Male
MH  - Mice
MH  - Mice, Transgenic
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - beta-Arrestin 2/*physiology
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
OTO - NOTNLM
OT  - Glucose metabolism
OT  - Irisin
OT  - Type 2 diabetes
OT  - p38 MAPK
OT  - beta-arrestin-2
EDAT- 2017/09/11 06:00
MHDA- 2017/11/04 06:00
CRDT- 2017/09/11 06:00
PHST- 2017/05/02 00:00 [received]
PHST- 2017/08/14 00:00 [revised]
PHST- 2017/09/05 00:00 [accepted]
PHST- 2017/09/11 06:00 [pubmed]
PHST- 2017/11/04 06:00 [medline]
PHST- 2017/09/11 06:00 [entrez]
AID - S0014-4827(17)30476-7 [pii]
AID - 10.1016/j.yexcr.2017.09.006 [doi]
PST - ppublish
SO  - Exp Cell Res. 2017 Nov 15;360(2):199-204. doi: 10.1016/j.yexcr.2017.09.006. Epub 
      2017 Sep 6.